0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > LRRK2

LRRK2

Brief Information

Name:Leucine-rich repeat serine/threonine-protein kinase 2
Target Synonym:PARK8,LRRK2,Leucine Rich Repeat Kinase 2,Leucine-Rich Repeat Serine/Threonine-Protein Kinase 2,Parkinson Disease (Autosomal Dominant) 8,Augmented In Rheumatoid Arthritis 17,Dardarin,AURA17,RIPK7,ROCO2,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2,DKFZp434H2111,FLJ45829
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
LK2-H5243 Human Human LRRK2 Protein, His Tag
LK2-H5243-structure
LK2-H5245 Human Human LRRK2 (G2019S) Protein, His Tag
LK2-H5245-structure
ACRO Quality

Synonym Name

PARK8,Leu-rich repeat/LRR-containing protein kinase 2,Dardarin

Background

Leucine-rich repeat kinase 2 (LRRK2), also known as dardarin and PARK8, is a kinase enzyme that in humans is encoded by the LRRK2 gene. LRRK2 is a member of the leucine-rich repeat kinase family, which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, autophagy, and vesicle trafficking. Mutations in the LRRK2 gene causes one of the most common monogenic forms of Parkinson disease (PD) . Also, several polymorphic variants in LRRK2 also modulate risk of sporadic PD.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BIIB-094 BIIB-094; ION-859; IONIS-BIIB7Rx Phase 2 Clinical Biogen Inc Parkinson Disease Details
DNL-151 BIIB-122; DNL-151 Phase 2 Clinical F. Hoffmann-La Roche Ltd, Biogen Inc Parkinson Disease Details
VRN-01 VRN-01 Phase 1 Clinical Voronoi Inc Glioblastoma Details
GNE-0877 GNE-0877; DNL-201; DNL201 Phase 1 Clinical F. Hoffmann-La Roche Ltd, Genentech Inc Parkinson Disease Details
ARV-102 ARV-102 Phase 1 Clinical Arvinas Inc Neurodegenerative Diseases Details
NEU-411 NEU-411 Phase 1 Clinical Details
FB418 FB418 Phase 1 Clinical 1st Biotherapeutics Inc Parkinsonian Disorders; Parkinson Disease; Amyotrophic Lateral Sclerosis Details
WXWH0226 WXWH0226; WXWH-0226 Phase 1 Clinical Guizhou Inochini Technology Co Ltd, Wuxi Apptec Co Ltd Parkinson Disease Details
DNL-201 DNL-201 F. Hoffmann-La Roche Ltd Details
BIIB-094 BIIB-094; ION-859; IONIS-BIIB7Rx Phase 2 Clinical Biogen Inc Parkinson Disease Details
DNL-151 BIIB-122; DNL-151 Phase 2 Clinical F. Hoffmann-La Roche Ltd, Biogen Inc Parkinson Disease Details
VRN-01 VRN-01 Phase 1 Clinical Voronoi Inc Glioblastoma Details
GNE-0877 GNE-0877; DNL-201; DNL201 Phase 1 Clinical F. Hoffmann-La Roche Ltd, Genentech Inc Parkinson Disease Details
ARV-102 ARV-102 Phase 1 Clinical Arvinas Inc Neurodegenerative Diseases Details
NEU-411 NEU-411 Phase 1 Clinical Details
FB418 FB418 Phase 1 Clinical 1st Biotherapeutics Inc Parkinsonian Disorders; Parkinson Disease; Amyotrophic Lateral Sclerosis Details
WXWH0226 WXWH0226; WXWH-0226 Phase 1 Clinical Guizhou Inochini Technology Co Ltd, Wuxi Apptec Co Ltd Parkinson Disease Details
DNL-201 DNL-201 F. Hoffmann-La Roche Ltd Details

This web search service is supported by Google Inc.

totop

Laisser un message